Global
Our Story

Share the latest information

Report on the 29th ERS (European Respiratory Society Annual Conference) Conference of Loki Biology
2019-10-10
312

From September 28 to October 2, 2019, the 29th ERS (European Respiratory Society Annual Conference) was held in Madrid, Spain. More than 20000 colleagues from all over the world participated in the event. This ERS meeting covered the key topics of respiratory medicine in 14 scientific fields, including tuberculosis, lung cancer, chronic and acute respiratory failure, sleep disordered breathing, interstitial lung disease, pneumonia, cystic fibrosis, COPD and asthma. (ERS is one of the leading medical institutions in the respiratory field. It is an international organization that brings together doctors, healthcare professionals, scientists and other experts in the respiratory field. Its members are distributed in more than 140 countries around the world. The mission of ERS is to promote lung health, alleviate the pain of diseases and promote the medical standards of the global respiratory system.)

The late breaking conference summary submitted by Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. was honored to be accepted by the conference, and was invited to send representatives to participate in the event.



Dr. Wan Yakun, the general manager of the company, was invited to attend the special session of "Treatment of asthmawith momoclonic antibiotics" and gave a wonderful speech.



During the poster exhibition after the meeting, many foreign counterparts came to consult the relevant information, expressed great interest in the asthma treatment drug independently developed by Loki Biologics for respiratory administration, and expressed the hope that Loki Biologics could promote the drug to the clinic as soon as possible, benefiting many patients with moderate and severe asthma at home and abroad.



Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd., located in the Shanghai International Medical Park, is an innovative enterprise focusing on the development of new nano-antibody drugs. The company's R&D pipeline mainly covers tumor immunotherapy, autoimmune diseases, ophthalmic diseases and CART treatment.